13D Filing: Orbimed Israel Biofund GP Limited Partnership and Novus Therapeutics Inc. (NVUS)

Page 1 of 9

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
OrbiMed Israel BioFund GP Limited Partnership 0 2,537,110 0 2,537,110 2,537,110 36.2%
OrbiMed Israel GP Ltd 0 2,537,110 0 2,537,110 2,537,110 36.2%

Page 1 of 9 – SEC Filing


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
Novus Therapeutics, Inc.

(Name of Issuer)
Common Stock, par value $0.001 per share

(Title of Class of Securities)
67011N105

(CUSIP Number)
OrbiMed Israel BioFund GP Limited Partnership
OrbiMed Israel GP Ltd.
Nissim Darvish
89 Medinat HaYehudim St.
Building E, 11th Floor
Herzliya 46766, Israel
Telephone: 972 73 2822600
(Name, Address and Telephone Number of Person Authorized
 to Receive Notices and Communications)
May 9, 2017

(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box ☐.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7(b) for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Eledon Pharmaceuticals Inc. (NASDAQ:ELDN)

Page 1 of 9